These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 24463381)

  • 21. Implantable defibrillators in primary prevention of genetic arrhythmias. A shocking choice?
    Corrado D; Link MS; Schwartz PJ
    Eur Heart J; 2022 Aug; 43(32):3029-3040. PubMed ID: 35725934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Arrhythmogenic Right Ventricular Cardiomyopathy: Risk Stratification and Indications for Defibrillator Therapy.
    Zorzi A; Rigato I; Bauce B; Pilichou K; Basso C; Thiene G; Iliceto S; Corrado D
    Curr Cardiol Rep; 2016 Jun; 18(6):57. PubMed ID: 27147509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia.
    Corrado D; Leoni L; Link MS; Della Bella P; Gaita F; Curnis A; Salerno JU; Igidbashian D; Raviele A; Disertori M; Zanotto G; Verlato R; Vergara G; Delise P; Turrini P; Basso C; Naccarella F; Maddalena F; Estes NA; Buja G; Thiene G
    Circulation; 2003 Dec; 108(25):3084-91. PubMed ID: 14638546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypertrophic Cardiomyopathy and Implantable Defibrillators in Sweden: Inappropriate Shocks and Complications Requiring Surgery.
    Magnusson P; Gadler F; Liv P; Mörner S
    J Cardiovasc Electrophysiol; 2015 Oct; 26(10):1088-94. PubMed ID: 26178879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of ventricular fibrillation rather than ventricular tachycardia predicts tachyarrhythmia recurrences in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillator for secondary prophylaxis.
    Rolf S; Haverkamp W; Borggrefe M; Breithardt G; Bocker D
    Europace; 2009 Mar; 11(3):289-96. PubMed ID: 19095687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?
    Ellenbogen KA; Levine JH; Berger RD; Daubert JP; Winters SL; Greenstein E; Shalaby A; Schaechter A; Subacius H; Kadish A;
    Circulation; 2006 Feb; 113(6):776-82. PubMed ID: 16461817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population.
    Obeyesekere MN; Chan W; Stub D; Prabhu S; Teo EP; Toogood G; Mariani J; Broughton A; Kistler PM
    Pacing Clin Electrophysiol; 2010 Jun; 33(6):696-704. PubMed ID: 20059719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Wearable cardioverter-defibrillator as a bridge to cardiac transplantation: A national database analysis.
    Opreanu M; Wan C; Singh V; Salehi N; Ahmad J; Szymkiewicz SJ; Thakur RK
    J Heart Lung Transplant; 2015 Oct; 34(10):1305-9. PubMed ID: 26094085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: data from the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) trial.
    Kloppe A; Proclemer A; Arenal A; Lunati M; Martìnez Ferrer JB; Hersi A; Gulaj M; Wijffels MC; Santi E; Manotta L; Mangoni L; Gasparini M
    Circulation; 2014 Jul; 130(4):308-14. PubMed ID: 24838360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risks and challenges of implantable cardioverter-defibrillators in young adults.
    Sherrid MV; Daubert JP
    Prog Cardiovasc Dis; 2008; 51(3):237-63. PubMed ID: 19026858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implantable cardioverter defibrillator therapy for prevention of sudden cardiac death in children in the Netherlands.
    Heersche JH; Blom NA; van de Heuvel F; Blank C; Reimer AG; Clur SA; Witsenburg M; ten Harkel AD
    Pacing Clin Electrophysiol; 2010 Feb; 33(2):179-85. PubMed ID: 20025697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective implantation of cardioverter-defibrillators in patients with genetic heart disease and sudden death risk.
    Kamath GS; Mittal S; Sherrid MV
    Anadolu Kardiyol Derg; 2009 Dec; 9 Suppl 2():32-40. PubMed ID: 20089485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How are European patients at risk of malignant arrhythmias or sudden cardiac death identified and informed about their risk profile: results of the European Heart Rhythm Association survey.
    Proclemer A; Bongiorni MG; Dagres N; Sciaraffia E; Todd D; Blomstrom-Lundqvist C;
    Europace; 2015 Jun; 17(6):994-8. PubMed ID: 26023178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subcutaneous implantable cardioverter-defibrillator: Initial experience.
    Galvão P; Cavaco D; Adragão P; Costa F; Carmo P; Morgado F; Bernardo R; Nunes M; Abecasis M; Neves J; Mendes M
    Rev Port Cardiol; 2014 Sep; 33(9):511-7. PubMed ID: 25242675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk stratification for sudden death in arrhythmogenic right ventricular cardiomyopathy.
    Cadrin-Tourigny J; Tadros R; Talajic M; Rivard L; Abadir S; Khairy P
    Expert Rev Cardiovasc Ther; 2015 Jun; 13(6):653-64. PubMed ID: 25947965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS
    J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of transvenous vs subcutaneous defibrillator therapy in patients with cardiac arrhythmia syndromes and genetic cardiomyopathies.
    Kuschyk J; Müller-Leisse J; Duncker D; Tülümen E; Fastenrath F; Fastner C; Kruska M; Akin I; Liebe V; Borggrefe M; Veltmann C; Rudic B
    Int J Cardiol; 2021 Jan; 323():100-105. PubMed ID: 32871189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implantable cardioverter-defibrillator: present and future indications.
    Block M; Scheld H; Breithardt G
    Arch Mal Coeur Vaiss; 1996 Feb; 89 Spec No 1():141-7. PubMed ID: 8734176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of sudden cardiac death: the role of the implantable cardioverter-defibrillator.
    Sinha SK; Mehta D; Gomes JA
    Mt Sinai J Med; 2005 Jan; 72(1):1-9. PubMed ID: 15682255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes in patients with sustained ventricular tachyarrhythmias occurring within 48 h of acute myocardial infarction: when is ICD appropriate?
    Liang JJ; Hodge DO; Mehta RA; Russo AM; Prasad A; Cha YM
    Europace; 2014 Dec; 16(12):1759-66. PubMed ID: 25100756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.